Quantitative assessment of the JAK2 V617F allele burden: Equivalent levels in peripheral blood and bone marrow [3]

Leukemia

Volumn 22, Issue 1, 2008, Pages 194-195

  Larsen, T S ^a   Pallisgaard, N ^a   Moller M B ^a   Hasselbalch, H C ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ALLELE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DNA EXTRACTION; GENE MUTATION; HOMOZYGOTE; HUMAN; HUMAN CELL; LETTER; LEUKOCYTE; LEUKOPENIA; MUTATIONAL ANALYSIS; MYELODYSPLASIA; MYELOID METAPLASIA; PHENOTYPE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 38349025467     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404861     Document Type: Letter

References (8)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
3. Gattenlohner S, Peter C, Bonengel M, Einsele H, Bargou R, Muller-Hermelink HK et al. Detecting the JAK2 V617F mutation in fresh and 'historic' blood and bone marrow. Leukemia 2007; 21 1559-1662.
4. Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N et al Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007; published online 3 May.
5. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombo-cythemia. Blood 2007; Published online 22 March.
6. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R et al The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631-635.
7. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006; 20: 1055-1060.
8. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136: 745-751.